Faes Farma SA

FAE

Equity

ISIN ES0134950F36 / Valor 2837976

BME Bolsas y Mercados Espanoles - Renta Variable (2024-11-19)

EUR 3.48+0.29%

Faes Farma SA
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Faes Farma SA is a pharmaceutical company based in Leioa, Spain, with additional offices and subsidiaries in various countries around the world. The company is primarily focused on the research, development, manufacturing, and marketing of prescription medicines, healthcare products, and animal nutrition products. Faes Farma SA is actively engaged in the pharmaceutical industry, producing a range of products to meet the needs of healthcare professionals and consumers globally.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Faes Farma SA reported a positive start to 2024, with revenue growth driven mainly by the strong performance of its pharmaceutical segment in both Spain and international markets. For Q1 2024, the company achieved a total income of €139.4 million, reflecting a 7% increase compared to the same period in the previous year.

Profit Increase

In Q1 2024, Faes Farma SA experienced double-digit profit growth, contributing to an increase in cash generation. The company's net profit for the quarter rose by 10% to €30.4 million, up from €27.7 million in Q1 2023. This growth was supported by the completion of the final phases of the Derio and ISF industrial investments.

Pharma Segment Performance

The pharmaceutical segment of Faes Farma SA showed solid growth across its entire portfolio. The top three molecules—Bilastine, Calcifediol, and Mesalazine—contributed significantly to this performance. Bilastine, in particular, saw growth in all business areas, driven by new ophthalmic and orodispersible presentations, as well as strong international performance.

International Business Expansion

Faes Farma SA's international business continued to expand, with total international income reaching €80.4 million in Q1 2024, a 6% increase from the previous year. The LATAM subsidiaries, especially in Mexico and Ecuador, showed notable growth, driven by the performance of Calcifediol. The company also saw positive results from its new Middle East and Africa (MEA) projects.

2024 Outlook

Looking ahead, Faes Farma SA expects to continue its growth trajectory in 2024, particularly driven by its international business expansion. The company anticipates a total income growth of 6-8% and an EBITDA growth of 3-5% for the year. Despite some challenges, such as increased personnel costs and price reductions for Bilastine in Spain, the company remains optimistic about its prospects.

Summarized from source with an LLMView Source

Key figures

14.5%1Y

0.46%3Y

-25.9%5Y

Performance

14.9%1Y

18.5%3Y

24.0%5Y

Volatility